Related Experiment Video
Updated: Aug 18, 2026

Using the Threat Probability Task to Assess Anxiety and Fear During Uncertain and Certain Threat
Published on: September 12, 2014
Evidence-based pharmacotherapy of panic disorder
Abraham Bakker1, Anton J L M van Balkom, Dan J Stein
1National Centre for Eating Disorders, Robert Fleury Stichting, Leidschendam, The Netherlands. A.Bakker@robertfleury.nl
Abstract:
This paper reviews the literature on the pharmacotherapy of panic disorder, in order to address the questions (1) what is the first-line pharmacotherapy of choice for panic disorder?, (2) for how long should maintenance pharmacotherapy be continued, and (3) what is the optimal approach to the treatment-refractory patient with panic disorder. A MEDLINE search (1966-2003) was undertaken to collate randomized controlled trials of pharmacotherapy in panic disorder. A review of the evidence indicates that SSRIs are currently the first line agent of choice in panic disorder, and that pharmacotherapy should be continued for at least 1 year. There has been relatively little research on the pharmacotherapy of treatment-refractory panic disorder, and this area requires future attention.
Related Concept Videos
Panic Disorder
Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
Anxiolytic Drugs: Benzodiazepines and Buspirone
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy